Editors' ChoiceCancer

Uncovering the FACTs in neuroblastoma

See allHide authors and affiliations

Science Signaling  10 Nov 2015:
Vol. 8, Issue 402, pp. ec335
DOI: 10.1126/scisignal.aad8178

Neuroblastoma is a common pediatric cancer of the nervous system, and tumors with amplifications of the MYC oncogene are particularly aggressive. Carter et al. identified FACT, which is a histone chaperone that participates in nucleosome assembly, as a mediator of MYC signaling in neuroblastoma and demonstrated its role in a feedback loop that allows tumor cells to maintain a high expression of both MYC and FACT. Curaxins, which are drugs that inhibit FACT, synergized with standard genotoxic chemotherapy to kill cancer cells and treat neuroblastoma in mouse models.

D. R. Carter, J. Murray, B. B. Cheung, L. Gamble, J. Koach, J. Tsang, S. Sutton, H. Kalla, S. Syed, A. J. Gifford, N. Issaeva, A. Biktasova, B. Atmadibrata, Y. Sun, N. Sokolowski, D. Ling, P. Y. Kim, H. Webber, A. Clark, M. Ruhle, B. Liu, A. Oberthuer, M. Fischer, J. Byrne, F. Saletta, L. M. Thwe, A. Purmal, G. Haderski, C. Burkhart, F. Speleman, K. De Preter, A. Beckers, D. S. Ziegler, T. Liu, K. V. Gurova, A. V. Gudkov, M. D. Norris, M. Haber, G. M. Marshall, Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma. Sci. Transl. Med. 7, 312ra176 (2015). [Abstract]

Stay Connected to Science Signaling